Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; sodium chloride; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: threonine; polysorbate 20; urea; water for injections; dibasic sodium phosphate dodecahydrate; glutamic acid; leucine; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; phenylalanine; glycine; isoleucine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 20000 iu/ml - injection - excipient ingredients: polysorbate 20; monobasic sodium phosphate; sodium chloride; urea; isoleucine; glycine; threonine; calcium chloride dihydrate; glutamic acid; dibasic sodium phosphate dodecahydrate; phenylalanine; leucine; water for injections - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: glutamic acid; leucine; isoleucine; polysorbate 20; water for injections; dibasic sodium phosphate dodecahydrate; urea; monobasic sodium phosphate; phenylalanine; threonine; calcium chloride dihydrate; glycine; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 13333.33 iu/ml - injection - excipient ingredients: leucine; phenylalanine; polysorbate 20; glycine; urea; water for injections; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; threonine; glutamic acid; isoleucine; dibasic sodium phosphate dodecahydrate - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.